Out of every 5000-10,000 compounds, only five make it into human tests. Out of those five that are tested in humans, one makes it to the market and to the patients that need them. Linda Marsa of the Atlantic recently took an in-depth look at these compounds and asked a very important question: why isn't the data from all of those tests used to find out what other effective uses a medication can have? It's a way to combat the rising costs of medication, often driven higher by the lengthy and often in-effective clinical trial process.
What Linda proposes is that we take the data from clinical trials and look at the results by gene activity. What does that medication do? What can be the most successful this to blocking that pathway? But, as we know, there are often difficulties with the access that is allowed to the information. With the publicly available information, much have this has already been done. Stanford researchers have already begun testing these theories on several matters: Can an anti-ulcer medication that’s available on pharmacy shelves combat the most common form of lung cancer? Will we soon be using an old epilepsy drug to quell symptoms of inflammatory bowel disease, or could we enlist a little-used class of antidepressants to battle a particularly deadly type of lung disease for which we have few effective therapies?
This March at Partnerships in Clinical Trials, Cross Industry Collaboration Discussion: Opportunities for Innovation Across the Entire Value Chain will gather professionals including Deirdre BeVard, VP, Clinical Operations, Endo Pharmaceuticals; Steve Miller, SVP & Chief Medical Officer, Express Scripts; Jodie Morrison, CEO, Tokai Pharmaceuticals; and Dalvir Gill, PhD, CEO, TransCelerate BioPharma Inc to discuss the current state of the industry and how collaboration and innovation can work together to move the industry forward. For more information on this session, download the agenda. If you'd like to join us this March 30-April 2, 2014 in Las Vegas, as a reader of this blog, when you register to join us and mention code XP1900BLOG, you can save $100 off the standard rate!
What do you see as the positives and negatives to sharing clinical trials data as a professional in the clinical trials industry?
The Partnerships in Clinical Trials Blog focuses on optimization intelligence, regulatory trends and globalization strategies for both sponsors and CROs. It is supported by a number of industry events.
Would you like to guest blog on our site? Or send us feedback? Send an email to email@example.com.